Enanta Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 145

Market Cap: $275.6M

Website

Introduction: Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Clinical Trials

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Phase 1

Terminated

Conditions: Chronic Hepatitis B Virus Infection

Interventions: Drug: Placebo (Part 1)
Drug: EDP-721 (Part 2)
Drug: Placebo (Part 2)
Drug: EDP-721
Drug: EDP-514

First Posted Date: 2021-07-21

Last Posted Date: 2022-02-14

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 26

Registration Number: NCT04971512

Locations: 🇳🇿
New Zealand Clinical Research Ltd, Auckland, New Zealand

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Phase 1

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Drug: EDP-938

First Posted Date: 2021-06-16

Last Posted Date: 2022-03-23

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 8

Registration Number: NCT04927793

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

Phase 1

Completed

Conditions: RSV Infection

Interventions: Drug: EDP-938
Drug: Fluconazole

First Posted Date: 2021-05-04

Last Posted Date: 2021-05-04

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 24

Registration Number: NCT04871724

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States

A Study to Evaluate EDP 938 Regimens in Children With RSV

Phase 2

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Drug: Placebo
Drug: EDP-938

First Posted Date: 2021-03-25

Last Posted Date: 2024-10-15

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 96

Registration Number: NCT04816721

Locations: 🇺🇸
Memorial Care Miller Children's and Women's Hospital, Long Beach, California, United States
🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸
UC Davis, Sacramento, California, United States

and more 75 locations

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Drug: EDP-514
Drug: Quinidine
Drug: Carbamazepin
Drug: Itraconazole

First Posted Date: 2021-03-05

Last Posted Date: 2021-08-16

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 72

Registration Number: NCT04783753

Locations: 🇺🇸
Pharmaceutical Research Association, Lenexa, Kansas, United States

Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

Phase 2

Terminated

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Drug: EDP-938

First Posted Date: 2020-11-18

Last Posted Date: 2024-08-22

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 9

Registration Number: NCT04633187

Locations: 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇬🇷
Evangelismos General Hospital of Athens, Athens, Greece
🇹🇷
Ege Universitesi Tip Fakultesi Hastanesi, Bornova, Izmir, Turkey

and more 61 locations

A Study of EDP-297 in Healthy Subjects

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

Interventions: Drug: Placebo
Drug: EDP-297

First Posted Date: 2020-09-22

Last Posted Date: 2021-10-29

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 82

Registration Number: NCT04559126

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: RSV Infection

Interventions: Drug: EDP-938
Drug: Tacrolimus
Drug: Dabigatran
Drug: Rosuvastatin
Drug: Midazolam

First Posted Date: 2020-08-04

Last Posted Date: 2021-10-13

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 89

Registration Number: NCT04498741

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Phase 1

Completed

Conditions: Chronic HBV Infection

Interventions: Drug: Placebo
Drug: EDP-514

First Posted Date: 2020-07-14

Last Posted Date: 2022-01-11

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 25

Registration Number: NCT04470388

Locations: 🇨🇳
E-Da Hospital/E-DA Cancer Hospital, Kaohsiung, Taiwan
🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan

and more 7 locations

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Phase 2

Terminated

Conditions: Non-Alcoholic Steatohepatitis

Interventions: Drug: EDP-305 2 mg
Drug: Placebo
Drug: EDP-305 1.5 mg

First Posted Date: 2020-05-07

Last Posted Date: 2023-05-19

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 98

Registration Number: NCT04378010

Locations: 🇺🇸
Paradigm Clinical Research Institute, Torrance, California, United States
🇺🇸
Universal Axon Clinical Research, Doral, Florida, United States
🇺🇸
San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States

and more 76 locations

Home Terms & Conditions Privacy Policy